Anderson, P M <br/><br/>
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.  [electronic resource] 

 -  Pediatric blood & cancer  Feb 2014 
 - 238-44 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.24686  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylmuramyl-Alanyl-Isoglutamine--administration & dosage<br/>Adolescent<br/>Adult<br/>Bone Neoplasms--drug therapy<br/>Child<br/>Child, Preschool<br/>Drug-Related Side Effects and Adverse Reactions<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local--drug therapy<br/>Osteosarcoma--drug therapy<br/>Phosphatidylethanolamines--administration & dosage<br/>Prognosis<br/>Safety<br/>Survival Rate<br/>Tissue Distribution<br/>Young Adult